Güler, Rezan
Svedmark, Siri Flemming
Abouzayed, Ayman
Orlova, Anna
Löfblom, John
Funding for this research was provided by:
Cancerfonden (CAN 2017/425 (A.O.), CAN 2017/649 (J.L.))
Vetenskapsrådet (2015-02509 (A.O.), 2019-05115 (J.L.))
VINNOVA (2019/00104 (J.L.))
Wallenberg Center for Protein Technology
Kungliga Tekniska Hogskolan
Article History
Received: 29 June 2020
Accepted: 23 September 2020
First Online: 23 October 2020
Competing interests
: AO is a member of the scientific advisory board of Affibody AB. AO is a minority share owner of Affibody AB. Affibody AB holds intellectual property rights and trademarks for Affibody molecules. Remaining authors declare no potential conflict of interest.